

Non Alcoholic Steato-Hepatitis Chronic Kidney Disease

**A study of a new medicine (fazpilodemab) in people with a type of liver disease called non-alcoholic steatohepatitis or NASH**

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

|                                   |                                     |  |
|-----------------------------------|-------------------------------------|--|
| <b>Trial Status</b><br>Terminated | <b>Trial Runs In</b><br>5 Countries | <b>Trial Identifier</b><br>NCT04171765 GC41033 |
|-----------------------------------|-------------------------------------|--|

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

***Trial Summary:***

This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).

|  |                         |
|--|-------------------------|
| <b>Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)</b><br>Sponsor | <b>Phase 2</b><br>Phase |
|--|-------------------------|

---

**NCT04171765 GC41033**  
Trial Identifiers

---

***Eligibility Criteria:***

|                      |  |                                 |
|----------------------|--|---------------------------------|
| <b>Gender</b><br>All | <b>Age</b><br>>=18 Years & <= 75 Years | <b>Healthy Volunteers</b><br>No |
|----------------------|--|---------------------------------|

---